Related Experiment Video
Updated: Nov 8, 2025

07:49
Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice
Published on: June 2, 2022
3.5K
Diet-Microbiota-Brain Axis in Alzheimer's Disease
Halle J Kincaid1, Ravinder Nagpal2, Hariom Yadav1
1Department of Internal Medicine-Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Annals of Nutrition & Metabolism
|April 27, 2021
Summary
Alzheimer's disease (AD) is linked to gut bacteria changes. Diet impacts the gut-brain axis, suggesting nutritional strategies may help prevent or treat AD by modulating gut microbiota.
Area of Science:
- Neuroscience
- Microbiology
- Gastroenterology
Background:
- Alzheimer's disease (AD) is a progressive dementia affecting cognition and function.
- The exact cause of AD remains unknown, with no current preventative or treatment options.
- Distinct gut microbiota compositions are observed in AD patients compared to healthy individuals.
Purpose of the Study:
- To explore the connection between the gut microbiota and Alzheimer's disease (AD).
- To investigate how diet influences the gut-brain axis in the context of AD.
- To identify potential nutritional strategies for AD prevention and treatment by targeting microbiota.
Main Methods:
- Review of emerging evidence linking gut microbiota, diet, and AD.
- Analysis of the gut-brain axis communication pathways.
- Discussion of microbiota metabolites' role in AD pathogenesis.
Main Results:
- Gut microbiota composition differs in individuals with AD.
- Diet significantly modulates gut microbiota and influences brain health.
- Gut microbiota metabolites can impact AD progression and cognitive decline.
Conclusions:
- The gut-brain axis plays a critical role in AD.
- Dietary interventions targeting gut microbiota may offer novel therapeutic avenues for AD.
- Modulating gut microbiota through nutrition shows promise for preventing or delaying AD progression.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
990
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
990
Alzheimer's Disease: Treatment
488
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
488
Role of Neurotransmitters in Memory
1.8K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
1.8K

